RenovoRx Introduces Innovative Pharmacokinetic Data
RenovoRx, Inc. (Nasdaq: RNXT) is a leading life sciences company dedicated to pioneering novel targeted oncology therapies. Recently, the company announced a significant milestone in cancer treatment with its unique delivery platform, RenovoCath. This platform focuses on improving therapeutic interventions for patients suffering from locally advanced pancreatic cancer (LAPC). RenovoRx is excited to share promising pharmacokinetic (PK) data stemming from its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.
Important Presentation at ASCO GI 2025
The tantalizing data was presented at a prestigious gathering - the ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025. The presentation was led by Dr. Paula Novelli from the University of Pittsburgh Medical Center. This event brings together some of the brightest minds in oncology to advance the science of cancer treatment. Dr. Novelli and her team combined efforts to deliver insights from their study that compares two different methods of administering the drug gemcitabine in patients with LAPC.
Understanding the Study Comparison
The presentation, titled “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial,” provides an enlightening view of drug delivery. This phase 3 clinical trial examines the effectiveness of using the RenovoCath delivery system to administer intra-arterial gemcitabine (IAG). This method was compared with the standard approach of intravenous gemcitabine, which is traditionally used for LAPC patients.
Results That Matter for Patients
The results are compelling. RenovoRx's IAG method achieved a notable decrease in systemic levels of gemcitabine when juxtaposed against the standard intravenous administration. Moreover, this method not only ensures increased potency of the drug at the tumor site but also provides a potential reduction in the adverse systemic side effects associated with traditional chemotherapy.
TAMP’s Unique Therapeutic Approach
The TAMP therapy platform is designed to administer precise and targeted drug delivery. Its sophisticated design allows for the effective treatment of the tumor while aiming to lessen overall toxicity for the patient. This localized approach provides hope for patients with LAPC, a condition known for its challenging prognosis.
Expert Insights on the Findings
Dr. Novelli emphasized the significance of the new findings, stating, “Pancreatic cancer remains one of the most challenging cancers to treat, and this new data further highlights the potential of RenovoRx’s TAMP therapy platform as a transformative therapeutic option.” The dual benefits of increased drug delivery efficiency, coupled with reduced systemic exposure, underscore the potential of TAMP to embody a game-changing approach in combating pancreatic cancer.
About the TIGeR-PaC Clinical Trial
The TIGeR-PaC trial is an ongoing Phase III randomized multi-center study that serves as the backbone for assessing the effectiveness of the TAMP therapy platform. As part of this study, RenovoRx's first product candidate utilizes TAMP technology for the precise intra-arterial delivery of gemcitabine directly to the tumor. As of the last interim analysis, completed in early 2023, the Data Monitoring Committee endorsed the trial's continuation based on promising results.
What’s Next for the Clinical Trial?
The trial's primary endpoint focuses on Overall Survival, with secondary endpoints aiming to assess the therapeutic side effects compared to current standard treatment. The diligent efforts in the trial are expected to yield a second interim analysis soon, with patient enrollment targets set for completion in the following months.
About the RenovoCath Device
RenovoCath is a cutting-edge FDA-cleared device designed for delivering therapeutic agents, including chemotherapeutics, to targeted sites within the body. Its innovative design facilitates various applications, such as temporary vessel occlusion and infusion procedures, enhancing the efficacy and safety of cancer treatments.
RenovoRx is committed to advancing its TAMP technology while also pursuing potential commercialization strategies to ensure that their products reach the patients who need them most. Recent developments include securing initial purchase orders for the RenovoCath devices from reputable medical institutions.
Frequently Asked Questions
What is RenovoRx's recent achievement presented?
RenovoRx presented promising pharmacokinetic data on its Trans-Arterial Micro-Perfusion therapy platform at the ASCO GI 2025.
Who led the presentation of this significant research?
Dr. Paula Novelli from the University of Pittsburgh Medical Center presented the findings during the symposium.
What is the main focus of the TIGeR-PaC clinical trial?
The TIGeR-PaC trial focuses on evaluating the effectiveness of the TAMP therapy platform in treating locally advanced pancreatic cancer.
How does RenovoCath differ from traditional methods?
RenovoCath allows for intra-arterial administration of gemcitabine, aiming for increased efficacy and reduced systemic side effects compared to intravenous delivery.
What are the next steps for RenovoRx following the trial?
RenovoRx aims to complete patient enrollment by mid-2025 and continue to develop its commercialization strategies.
